<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2444-054X</journal-id>
<journal-title><![CDATA[Cirugía y cirujanos]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. cir.]]></abbrev-journal-title>
<issn>2444-054X</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Cirugía A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2444-054X2021000600703</article-id>
<article-id pub-id-type="doi">10.24875/ciru.20000773</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultado oncológico de linfadenectomía retroperitoneal por tumor residual posquimioterapia en cáncer germinal. Análisis retrospectivo de 15 años]]></article-title>
<article-title xml:lang="en"><![CDATA[Oncological outcomes of retroperitoneal node dissection for residual masses after chemotherapy in germ cell tumor. Retrospective analysis of 15 years]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piñón-Solis]]></surname>
<given-names><![CDATA[Enrique O.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-Ríos]]></surname>
<given-names><![CDATA[Miguel A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Scavuzzo]]></surname>
<given-names><![CDATA[Anna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Cervera]]></surname>
<given-names><![CDATA[Pedro F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cancerología Departamento de Urología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>89</volume>
<numero>6</numero>
<fpage>703</fpage>
<lpage>709</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2444-054X2021000600703&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2444-054X2021000600703&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2444-054X2021000600703&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Reportar nuestra experiencia en supervivencia y recurrencia en el manejo de masas residuales posquimioterapia con linfadenectomía retroperitoneal durante 15 años.  Método: Estudio retrospectivo de 2004 a 2019. Se incluyeron pacientes con diagnóstico de tumor de células germinales que habían recibido quimioterapia y presentaron una masa residual retroperitoneal en un solo centro y se les realizó linfadenectomía retroperitoneal. Se analizaron las características sociodemográficas, de supervivencia global e histológicas.  Resultados: Cumplían los criterios de inclusión 346 pacientes, con una media de edad de 27.6 años. El testículo más afectado fue el izquierdo, y la histología testicular más frecuente fue germinal mixto. La localización retroperitoneal más frecuente fue paraaórtica, el tipo de linfadenectomía más frecuente fue la estándar y la histología más frecuente fue la necrosis. Se presentó recurrencia en el 24.2% de los pacientes, en una media de 17.1 meses; al analizar los factores individuales, el más significativo fue el tipo de linfadenectomía. El estadio clínico, la histología del tumor retroperitoneal y el tipo de linfadenectomía influyen en la mortalidad. El seguimiento global fue de 141 meses, la supervivencia global fue del 85.5% y la supervivencia específica del cáncer fue del 86.1%, con media de 139.9 y 141 meses, respectivamente.  Conclusiones: La linfadenectomía retroperitoneal es efectiva en cuanto a supervivencia y recurrencia en la enfermedad avanzada en pacientes que presentan tumor retroperitoneal posquimioterapia, y aunque existe un claro beneficio en la resección de los tumores retroperitoneales en teratoma, existen factores condicionantes que deben ser analizados de manera individual.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To report experience in a hospital in Mexico regarding oncological results in overall survival (OS) and specific cancer survival (SCS), the presence of recurrence in the management of residual masses after chemotherapy with lymphadenectomy retroperitoneal for 15 years.  Method: Between 2004 and 2019, a retrospective study was carried out in a single centre with patients with a germ cell tumor diagnosis who have received first or second line of chemotherapy and who present retroperitoneal residual mass were included have performed RPLND. Sociodemographic characteristics were analyzed, overall and histological survival.  Results: 346 patients had inclusion criteria, mean age was 27.6 years, the most affected testis was the left, the most frequent testicular histology was mixed germline. The most frequent retroperitoneal location was paraortic, the most frequent type of RPLND was standard, the most frequent histology was necrosis. Recurrence occurred in 24.2%, mean of 17.1 months, when analyzing individual factors, the most significant was the type of RPLND. The clinical stage, histology of the retroperitoneal tumor and type of RPLND influence mortality. Global follow up of 141 months, OS was 85.5% and SCS was 86.1%, mean of 139.9 months and 141 months respectively.  Conclusions: RPLND is effective in survival and recurrence in advanced disease in patients who present postchemotherapy retroperitoneal tumor and although there is a clear benefit in the resection of retroperitoneal tumors in teratoma, there are conditioning factors that must be analyzed individually.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tumor germinal]]></kwd>
<kwd lng="es"><![CDATA[Linfadenectomía retroperitoneal]]></kwd>
<kwd lng="es"><![CDATA[Supervivencia global]]></kwd>
<kwd lng="es"><![CDATA[Tumor retroperitoneal]]></kwd>
<kwd lng="en"><![CDATA[Germ tumor]]></kwd>
<kwd lng="en"><![CDATA[Retroperitoneal lymphadenectomy]]></kwd>
<kwd lng="en"><![CDATA[Overall survival]]></kwd>
<kwd lng="en"><![CDATA[Retroperitoneal masses]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[La Vecchia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bosetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bertuccio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Negri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2010</year>
<volume>21</volume>
<page-range>1323-60</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>INEGI</collab>
<article-title xml:lang=""><![CDATA[Estadísticas de mortalidad]]></article-title>
<source><![CDATA[Cubos dinámicos]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kavoussi]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Novick]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Partin]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoplasias de los testículos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Kavoussi]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Novick]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Partin]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Campbell-Walsh Urología]]></source>
<year>2012</year>
<edition>10.ªed</edition>
<page-range>845-82</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[Globocan Cancer Observatory, 2018]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nigam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aschebrook-Kilfoy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shikanov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eggener]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009]]></article-title>
<source><![CDATA[World J Urol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>623-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghazarian]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Altekruse]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[McGlynn]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Future of testicular germ cell tumor incidence in the United States:forecast through 2026]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2017</year>
<volume>123</volume>
<page-range>2320-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Catalano]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Vogelzang]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Loehrer]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors:an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>1287-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>TIGER</collab>
<source><![CDATA[A randomised phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel followed by High-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woldu]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ci]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Freifeld]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Clinton]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Aydin]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice patterns and impact of postchemotherapy retroperitoneal lymph node dissection on testicular cancer outcomes]]></article-title>
<source><![CDATA[Eur Urol Oncol]]></source>
<year>2018</year>
<volume>1</volume>
<page-range>242-51</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavery]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bahnson]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Sharp]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Pohar]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors]]></article-title>
<source><![CDATA[Ther Adv Urol]]></source>
<year>2009</year>
<volume>1</volume>
<page-range>199-207</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartmann]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Candelaria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuczyk]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Schmoll]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>1997</year>
<volume>33</volume>
<page-range>843-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Bihrle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Donohue]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>6149-56</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Feifer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Carver]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical management of patients with advanced germ cell tumors following salvage chemotherapy:Memorial Sloan Kettering Cancer Center (MSKCC) experience]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2019</year>
<volume>124</volume>
<page-range>174-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Becerra]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Carver]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bajorin]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcome of patients with fibrosis/necrosis at post-chemotherapy retroperitoneal lymph node dissection for advanced germ cell tumors]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2017</year>
<volume>197</volume>
<page-range>391-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ehrlich]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Brames]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors:is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>531-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masterson]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Cary]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of modified templates in early and advanced stage nonseminomatous germ cell tumor]]></article-title>
<source><![CDATA[Adv Urol]]></source>
<year>2018</year>
<volume>2018</volume>
<page-range>6783147</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winter]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pfister]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Busch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bingöl]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ranft]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Schrader]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection:a multicenter analysis of the German Testicular Cancer Study Group]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2012</year>
<volume>61</volume>
<page-range>403-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capitanio]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Jeldres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Perrotte]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Isbarn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Crépel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cloutier]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2009</year>
<volume>74</volume>
<page-range>373-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cary]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Masterson]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Bihrle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary trends in postchemotherapy retroperitoneal lymph node dissection:additional procedures and perioperative complications]]></article-title>
<source><![CDATA[Urol Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>389.e15-21</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kotb]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Aldousari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brimo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tanguay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kassouf]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>97</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
